Aprea Therapeutics earnings release, May 13, 2026

Aprea Therapeutics, Inc. (APRE) · Form 8-K, Item 2.02 · Filed · SEC filing

​

​

Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

​

DOYLESTOWN, PA, May 13, 2026 (GLOBE NEWSWIRE) – Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.

“We are very encouraged by the progress made across both our clinical and corporate priorities during the first quarter of 2026, including two partial responses observed in the ACESOT-1051 trial evaluating APR-1051. One of these has been confirmed at a second imaging assessment and this patient remains on study,” said Oren Gilad, Ph.D., President and Chief Executive Officer of Aprea. “These efficacy results, coupled with the encouraging tolerability, support our precision medicine strategy and reinforce the potential of targeted therapies for patients who have limited treatment options. We look forward to presenting an update from ACESOT-1051 at ASCO 2026 and providing additional insight into APR-1051’s emerging clinical profile. The recent $30 million private placement significantly strengthens our balance sheet and enables us to meaningfully expand patient enrollment, generating the clinical data needed to inform the future clinical path for APR-1051. We are grateful for the trust and support of both new and existing investors, whose participation reflects confidence in our development strategy and the potential of our programs.”

Key Business Updates and Upcoming Key Milestones

ACESOT-1051: A Biomarker Focused, Phase 1 Trial of Oral WEE1 inhibitor, APR-1051

​

​

​

​

ABOYA-119: Clinical Trial Evaluating ATR inhibitor, ATRN-119

​

​

​

​

​

Corporate

​

Select Financial Results for the First Quarter Ended March 31, 2026

As of March 31, 2026, the Company reported cash and cash equivalents of $46.5 million compared to $14.6 million as of December 31, 2025. The Company believes that its cash and cash equivalents as of March 31, 2026 will be sufficient to meet its currently projected operating expenses and capital expenditure requirements into the first quarter of 2028.

For the first quarter ended March 31, 2026, the Company reported an operating loss of $3.4 million, compared to an operating loss of $4.1 million in the first quarter of 2025.

Research and Development (R&D) expenses were $1.6 million for the quarter ended March 31, 2026, compared to $2.5 million for the first quarter of 2025. The decrease in R&D expense was primarily related to a decrease of $0.8 million related to the ABOYA-119 clinical trial to evaluate ATRN-119, our clinical-stage oral small molecule inhibitor of ATR, which was voluntarily paused in October 2025.

General and Administrative (G&A) expenses were $1.8 million for each of the quarters ended March 31, 2026 and 2025.

The Company reported a net loss of $3.3 million or ($0.22) loss per basic share on approximately 14.7 million weighted-average common shares outstanding for the quarter ended March 31, 2026, compared to a net loss of $3.9 million ($0.66) per basic share on approximately 6.0 million weighted average common shares outstanding for the comparable period in 2025.

​

About Aprea

Aprea is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. The Company is pioneering a new approach to treat cancer by exploiting vulnerabilities associated with cancer cell mutations. This approach was developed to kill tumors while minimizing the effect on normal, healthy cells. Aprea’s technology has potential applications across multiple cancer types, enabling it to target a range of tumors, including ovarian, endometrial, colorectal and head and neck squamous cell carcinoma. The Company’s lead programs are APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and

​

​

​

ATRN-119, a small molecule ATR inhibitor, both in clinical development for solid tumor indications. For more information, please visit the Company website at www.aprea.com.

The Company may use, and intends to use, its investor relations website at https://ir.aprea.com/ as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.

​

Forward-Looking Statement

Financial statements

Income Statement

Aprea Therapeutics, Inc. — mmoyer@lifesciadvisors.com

Aprea Therapeutics, Inc. – Consolidated Statements of Operations and Comprehensive Loss – (Unaudited) – Three Months Ended March 31, – 2026Aprea Therapeutics, Inc. – Consolidated Statements of Operations and Comprehensive Loss – (Unaudited) – Three Months Ended March 31, – 2025
Grant revenue$—162,463
Operating expenses:Research and development1,611,1672,483,066
Operating expenses:General and administrative1,819,2451,764,979
Operating expenses:Total operating expenses3,430,4124,248,045
Operating expenses:Loss from operations-3,430,412-4,085,582
Other income (expense):Interest income, net134,784204,726
Other income (expense):Foreign currency gain (loss)7,711-51,803
Other income (expense):Total other income142,495152,923
Other income (expense):Net loss-3,287,917-3,932,659
Other comprehensive loss:Foreign currency translation9,014643
Other comprehensive loss:Total comprehensive loss-3,278,903-3,932,016
Other comprehensive loss:Net loss per share attributable to common stockholders, basic and diluted-0.22-0.66
Other comprehensive loss:Weighted-average common shares outstanding, basic and diluted14,685,4485,993,866

Balance Sheet

Aprea Therapeutics, Inc. — mmoyer@lifesciadvisors.com

Aprea Therapeutics, Inc. – Consolidated Balance Sheets – March 31, 2026 – (unaudited)Aprea Therapeutics, Inc. – Consolidated Balance Sheets – December 31, 2025
Current assets:Cash and cash equivalents46,466,20214,599,347
Current assets:Prepaid expenses and other current assets779,238961,899
Current assets:Total current assets47,245,44015,561,246
Current assets:Property and equipment, net54,37959,807
Current assets:Restricted cash41,40641,186
Current assets:Other noncurrent assets271,162271,162
Current assets:Total assets47,612,38715,933,401
Current liabilities:Accounts payable2,940,756713,668
Current liabilities:Accrued expenses2,355,8902,050,690
Current liabilities:Total current liabilities5,296,6462,764,358
Commitments and contingenciesSeries A convertible preferred stock, $0.001 par value, 40,000,000 shares authorized; 31,194 shares issued and outstanding at March 31, 2026 and December 31, 2025727,361727,361
Stockholders’ equity:Common stock, $0.001 par value, 400,000,000 shares authorized, 11,982,776 and 8,192,538 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively11,9838,192
Stockholders’ equity:Additional paid-in capital389,631,454356,709,645
Stockholders’ equity:Subscription Receivable-499,999
Stockholders’ equity:Accumulated other comprehensive loss-10,625,700-10,634,714
Stockholders’ equity:Accumulated deficit-336,929,358-333,641,441
Stockholders’ equity:Total stockholders’ equity41,588,38012,441,682
Stockholders’ equity:Total liabilities and stockholders' equity47,612,38715,933,401
Full release

Certain information contained in this press release includes “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended related to our study analyses, clinical trials, regulatory submissions, and projected cash position. We may, in some cases use terms such as “future,” “predicts,” “believes,” “potential,” “continue,” “anticipates,” “estimates,” “expects,” “plans,” “intends,” “targeting,” “confidence,” “may,” “could,” “might,” “likely,” “will,” “should” or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. Our forward-looking statements are based on current beliefs and expectations of our management team and on information currently available to management that involve risks, potential changes in circumstances, assumptions, and uncertainties. All statements contained in this press release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize, and achieve market acceptance of our current and planned products and services, our research and development efforts, including timing considerations and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. Any or all of the forward-looking statements may turn out to be wrong or be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. These forward-looking statements are subject to risks and uncertainties including, without limitation, risks related to the success, timing, and cost of our ongoing clinical trials and anticipated clinical trials for our current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including our ability to fully fund our disclosed clinical trials, which assumes no material changes to our currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim or preliminary results (including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of our ongoing clinical trials, our understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs, and our ability to predict clinical outcomes based on such preclinical and early clinical results, and the other risks, uncertainties, and other factors described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the U.S. Securities and Exchange Commission. For all these reasons, actual results and developments could be materially different from those expressed in or implied by our forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this press release. We undertake no obligation to update such forward-looking statements for any reason, except as required by law.

​

​

​

​

​

Investor Contact:

Mike Moyer

LifeSci Advisors mmoyer@lifesciadvisors.com

​

​

​

​

​

​

​

​

​

​

​

​

​

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Aprea Therapeutics earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.